Zhibin Chen, PhD; Martin J. Brodie, MD; Danny Liew, MD, PhD; et al.
free access
JAMA Neurol. 2018;75(3):279-286. doi:10.1001/jamaneurol.2017.3949
This longitudinal cohort study assessed treatment outcomes in patients with newly diagnosed epilepsy and calculated the probability of achieving seizure freedom with first, second, and successive drug regimens prescribed.
Yael Backner, MS; Joseph Kuchling, MD; Said Massarwa; et al.
free access
JAMA Neurol. 2018;75(3):287-295. doi:10.1001/jamaneurol.2017.3880
This study examines the anatomical and functional visual networks in patients with clinically isolated syndrome optic neuritis.
Carsten Finke, MD; Hanna Zimmermann, MSc; Florence Pache, MD; et al.
free access
JAMA Neurol. 2018;75(3):296-303. doi:10.1001/jamaneurol.2017.3890
This cross-sectional study examines adaptive visual network connectivity changes in neuromyelitis optica spectrum disorder.
Raul G. Nogueira, MD; Donald Frei, MD; Jawad F. Kirmani, MD; et al.
free access
JAMA Neurol. 2018;75(3):304-311. doi:10.1001/jamaneurol.2017.3967
This randomized clinical noninferiority trial assesses a novel 3-dimensional stent retriever when used in conjunction with aspiration-based mechanical thrombectomy compared with aspiration-based mechanical thrombectomy alone in patients with acute ischemic stroke.
Rachel Saunders-Pullman, MD, MPH; Anat Mirelman, PhD; Roy N. Alcalay, MD, MS; et al.
free access
JAMA Neurol. 2018;75(3):312-319. doi:10.1001/jamaneurol.2017.4019
This longitudinal study examines whether the course of Parkinson disease in patients with the LRRK2 mutation differs from the course of Parkinson disease in patients without the mutation.
Mathias Granqvist, MD; Malin Boremalm; Amyar Poorghobad, MD; et al.
free access
JAMA Neurol. 2018;75(3):320-327. doi:10.1001/jamaneurol.2017.4011
This observational cohort study assesses the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed relapsing-remitting multiple sclerosis compared with injectable disease-modifying treatments, dimethyl fumarate, fingolimod, or natalizumab.
Liana G. Apostolova, MD, MSc; Shannon L. Risacher, PhD; Tugce Duran, BS; et al.
free access
JAMA Neurol. 2018;75(3):328-341. doi:10.1001/jamaneurol.2017.4198
This study investigates the association of the top 20 Alzheimer disease risk variants with brain amyloidosis.
Miguel A. Santos-Santos, MD; Gil D. Rabinovici, MD; Leonardo Iaccarino, MSc; et al.
free access
JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309
This prospective case series examines the rates of positron emission tomography amyloid positivity in the main clinical variants of primary progressive aphasia.
Daniel Martinez-Ramirez, MD; Joohi Jimenez-Shahed, MD; James Frederick Leckman, MD; et al.
free access
JAMA Neurol. 2018;75(3):353-359. doi:10.1001/jamaneurol.2017.4317
This study uses patients in the International Deep Brain Stimulation Database and Registry to assess the efficacy and safety of deep brain stimulation in a multinational cohort of patients with Tourette syndrome.
Kimberly C. Paul, MPH, PhD; Jessica Schulz, cand MD; Jeff M. Bronstein, MD, PhD; et al.
free access
JAMA Neurol. 2018;75(3):360-366. doi:10.1001/jamaneurol.2017.4206
This population-based study investigates the cumulative association of established genetic risk factors for Parkinson disease with cognitive impairment and reexamines the association of the polygenetic risk score with motor progression and survival among patients with Parkinson disease.